Olema Pharmaceuticals, Inc. OLMA Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $52.55M+3.8% | $48.3M-65.4% | $35.26M-1.7% | $52.47M+211% | $50.64M+50.2% | ||
| $452.8M+32.4% | $457.14M+55.2% | $293.7M+64.2% | $309.44M+39.3% | $342.07M+58.9% | ||
| $7.88M+99.2% | $10.02M+128% | $5.37M+66.2% | $5.81M+88.5% | $3.96M+27.1% | ||
| $513.23M+29.4% | $515.45M+17.6% | $334.33M+53.4% | $367.73M+51.8% | $396.66M+57.3% | ||
| $921K-12.7% | $1.15M-12.8% | $1.42M-9.4% | $1.69M-7.1% | $1.06M-48.7% | ||
| $530.65M+29.5% | $533.43M+18.3% | $352.45M+53.1% | $382M+50.1% | $409.64M+55.3% | ||
| $3.72M+2,363% | $9.25M+107% | $3.47M+29.4% | $934K-78.5% | $151K-98.0% | ||
| $42.49M+70.7% | $41.43M+14.7% | $37.01M+37.7% | $31.08M+47.4% | $24.89M+42.1% | ||
| $956K-6.7% | $1.12M-4.1% | $1.17M+2.7% | $1.15M+4.5% | $1.03M-3.0% | ||
| $47.17M+81.0% | $51.8M+24.1% | $41.66M+35.7% | $33.16M+25.0% | $26.06M-0.6% | ||
| $0-100% | $69K-73.2% | $310K-44.8% | $602K-29.9% | $123K-89.3% | ||
| $956K-16.7% | $1.19M-16.5% | $1.48M-13.0% | $1.76M-10.6% | $1.15M-48.0% | ||
| $50.17M+91.6% | $54.87M+30.6% | $44.97M+43.8% | $36.77M+34.2% | $26.19M-4.3% | ||
| $8K+14.3% | $8K+14.3% | $7K+75.0% | $7K+75.0% | $7K+75.0% | ||
| $1.13B+33.4% | $1.08B+27.4% | $858.45M+43.1% | $854.19M+43.7% | $848.52M+48.1% | ||
| -$650.65M-39.8% | -$597.56M-37.3% | -$551.5M-37.3% | -$509.28M-38.8% | -$465.5M-38.3% | ||
| -$460K-210% | $621K+334% | $526K+13.4% | $314K+366% | $420K+4,300% | ||
| $480.48M+25.3% | $478.56M+17.0% | $307.49M+54.6% | $345.24M+52.0% | $383.45M+62.3% | ||
| $530.65M+29.5% | $533.43M+18.3% | $352.45M+53.1% | $382M+50.1% | $409.64M+55.3% | ||
| $452.8M+32.4% | $457.14M+55.2% | $293.7M+64.2% | $309.44M+39.3% | $342.07M+58.9% | ||
| $921K-12.7% | $1.15M-12.8% | $1.42M-9.4% | $1.69M-7.1% | $1.06M-48.7% | ||
| $921K-12.7% | $1.15M-12.8% | $1.42M-9.4% | $1.69M-7.1% | $1.06M-48.7% | ||
| $16.5M+38.4% | $16.83M+50.4% | $16.71M+57.4% | $12.59M+19.3% | $11.92M+24.8% | ||
| $921K-12.7% | $1.15M-12.8% | $1.42M-9.4% | $1.69M-7.1% | $1.06M-48.7% | ||
| $42.49M+70.7% | $41.43M+14.7% | $37.01M+37.7% | $31.08M+47.4% | $24.89M+42.1% | ||
| $3M— | $3M— | $3M— | $3M— | —— | ||
| $956K-16.7% | $1.19M-16.5% | $1.48M-13.0% | $1.76M-10.6% | $1.15M-48.0% | ||
| $8K+14.3% | $8K+14.3% | $7K+75.0% | $7K+75.0% | $7K+75.0% | ||
| $3M— | $3M— | $3M— | $3M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Olema Pharmaceuticals, Inc.'s total assets?
- Olema Pharmaceuticals, Inc. (OLMA) holds $530.6M in total assets, up 29.5% year over year.
- How much debt does Olema Pharmaceuticals, Inc. have?
- Olema Pharmaceuticals, Inc. carries $956.0K in total debt against $480.5M of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Olema Pharmaceuticals, Inc. have?
- Olema Pharmaceuticals, Inc. holds $52.5M in cash and equivalents.
- Can Olema Pharmaceuticals, Inc. cover its short-term obligations?
- Its current ratio is 10.88 — current assets exceed current liabilities.
- Where does Olema Pharmaceuticals, Inc.'s balance sheet data come from?
- Every line is extracted from Olema Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.